We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+22.96%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.54B
AUM Growth
+$187M
Cap. Flow
-$12.7M
Cap. Flow %
-0.82%
Top 10 Hldgs %
46.64%
Holding
69
New
11
Increased
6
Reduced
41
Closed
4

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$42M
2
ZGNX
Zogenix, Inc.
ZGNX
+$25.5M
3
TSRO
TESARO, Inc.
TSRO
+$24.7M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$14.8M
5
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$12.1M

Top Sells

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$18.2M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$15.1M
3
QTRX icon
Quanterix
QTRX
+$12.5M
4
BPMC
Blueprint Medicines
BPMC
+$11.8M
5
MTVA
MetaVia Inc
MTVA
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBIO
51
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.55M 0.3%
454,550
– –
EIDX
52
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$3.85M 0.25%
385,846
– –
COLL icon
53
Collegium Pharmaceutical
COLL
$1.16B
$3.69M 0.24%
250,000
-36,668
-13% -$650K
AKCA
54
PUT
DELISTED
Akcea Therapeutics Inc
AKCA
$3.5M 0.23%
+100,000
New +$3.03M
SGMO
55
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.39M 0.22%
200,000
-182,192
-48% -$2.77M
MGTX icon
56
MeiraGTx Holdings
MGTX
$1.16B
$3.25M 0.21%
238,579
-1
-0% -$11
ITRM
57
DELISTED
Iterum Therapeutics
ITRM
$3.2M 0.21%
31,798
-1,535
-5% -$200K
MRNS
58
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3M 0.2%
75,000
-44,528
-37% -$1.27M
TRIL
59
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.9M 0.19%
500,000
-73,208
-13% -$413K
XLRN
60
DELISTED
Acceleron Pharma
XLRN
$2.86M 0.19%
50,000
-21,667
-30% -$1.06M
CLSD
61
DELISTED
Clearside Biomedical
CLSD
$2.46M 0.16%
26,667
-53,333
-67% -$6.34M
ARQL
62
DELISTED
Arqule Inc
ARQL
$1.7M 0.11%
+300,000
New +$1.71M
QTRX icon
63
Quanterix
QTRX
$177M
$1.18M 0.08%
54,945
-792,843
-94% -$12.5M
ONSIW
64
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$9K ﹤0.01%
416,666
– –
CLRBW
65
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$4K ﹤0.01%
52,999
– –
INDP icon
66
Indaptus Therapeutics
INDP
$177M
– –
-345
Closed -$3.4M
PTGX icon
67
Protagonist Therapeutics
PTGX
$8.83B
– –
-382,139
Closed -$2.57M
VNDA icon
68
Vanda Pharmaceuticals
VNDA
$306M
– –
-957,821
Closed -$18.2M
MTVA
69
MetaVia Inc
MTVA
$7.69M
– –
-16
Closed -$10.6M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Cormorant Asset Management held 69 positions worth $1.54B, up 14% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q3 2018 filing shows 11 new, 6 increased, 41 reduced and 4 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,486,898 shares worth $43.4M. The largest sale was Vanda Pharmaceuticals, an estimated $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier.

  • Cormorant Asset Management's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,486,898 shares worth $43.4M.
  • Cormorant Asset Management added most to TESARO, Inc. in Q3 2018, an estimated $24.7M increase.
  • Cormorant Asset Management's biggest Q3 2018 reduction was Spectrum Pharmaceuticals Inc, cutting an estimated $15.1M.
  • Cormorant Asset Management fully exited Vanda Pharmaceuticals in Q3 2018, selling an estimated $18.2M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2018.
  • Cormorant Asset Management opened 11 new positions and closed 4 in Q3 2018.
  • Cormorant Asset Management's portfolio value rose 14% quarter-over-quarter to $1.54B.

Based on Cormorant Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.